VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia (VENEZE-AGA)

May 9, 2026 updated by: Chinmanat Lekhavat, Institute of Dermatology, Thailand

Effectiveness and Tolerability of VENEZE Peptide Factor Hair Serum for Pattern Hair Loss: A Randomized Double-blind Study

This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. Participants will be randomly assigned, in a double-blind manner, to receive either the peptide hair serum or topical minoxidil. The primary objective is to assess improvement in hair growth over the study period, including changes in hair density and hair thickness. Secondary outcomes will include safety and tolerability assessments. The findings of this study may provide evidence supporting an alternative treatment option for patients with androgenetic alopecia.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Androgenetic alopecia (AGA) is a common condition affecting both men and women and can significantly impact quality of life. Topical minoxidil is a widely used treatment; however, its effectiveness varies and it may cause local adverse effects in some patients. Peptide hair serums have emerged as a potential alternative, with proposed mechanisms including stimulation of hair follicle activity and promotion of hair growth.

This study aims to evaluate the efficacy and safety of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. The primary objective is to assess improvement in hair growth, including changes in hair density and hair thickness. Secondary objectives include evaluation of safety, tolerability, and patient-reported outcomes.

This is a randomized, double-blind, parallel-group study. Eligible participants with androgenetic alopecia will be randomly assigned to receive either the peptide-based hair serum or topical minoxidil. Treatments will be administered according to the study protocol over a defined study period.

Efficacy outcomes will include quantitative assessment of hair density and hair thickness. Safety will be evaluated through monitoring of adverse events and local tolerability.

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Suchanaree Laitrakul, MD
  • Phone Number: 1828 66023545222

Study Locations

  • Thailand
      • Bangkok, Thailand
        • Recruiting
        • Institute of dermatology
    • Bangkok
      • Bangkok, Bangkok, Thailand, 10400
        • Recruiting
        • Institute of dermatology
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or female participants aged ≥18 years.
  • Diagnosed with androgenetic alopecia (AGA): Norwood-Hamilton classification III-V in males or Ludwig classification I-II in females.
  • Able to read and write for completion of study questionnaires (e.g., Patient Global Assessment, Hair Growth Questionnaire).
  • Willing to comply with study procedures, including maintaining consistent hair color and hairstyle throughout the study.
  • Hair length in the non-balding area (vertex surrounding area) ≥2 cm at each visit.
  • Able to attend all scheduled visits during the 24-week study period.

Exclusion Criteria:

  • Presence of unstable or uncontrolled systemic diseases that may affect hair growth or loss within 6 months prior to screening (e.g., liver, renal, thyroid, cardiovascular, neurological diseases, diabetes, anemia).
  • History of malignancy within the past 5 years, except adequately treated basal cell carcinoma or squamous cell carcinoma.
  • Psychiatric disorders or other conditions that may affect participant safety or compliance.
  • Pregnant or breastfeeding women.

Hair and scalp-related exclusions:

  • Diffuse hair thinning involving the occipital area.
  • Scalp conditions or diseases affecting hair growth (e.g., tinea infection, non-AGA hair loss, psoriasis, uncontrolled seborrheic dermatitis).
  • History of hair transplantation at any time or hair extensions within 6 months prior to screening.
  • Use of cosmetic products for hair loss concealment within 2 weeks prior to screening.
  • Use of light/laser therapy on the scalp within 3 months prior to screening.
  • Use of supplements related to hair growth (e.g., zinc, biotin) within 3 months prior to screening.
  • Use of hair products containing active ingredients (e.g., caffeine, peptides) within 3 months prior to screening.
  • Hair procedures such as mesotherapy or stem cell injection within 3 months prior to screening.

Medication-related exclusions:

  • Known hypersensitivity to study-related products or ingredients.
  • Use of dutasteride within 12 months prior to screening.
  • Use of systemic cytotoxic agents.
  • Use of systemic glucocorticoids within 3 months prior to screening (except inhaled or topical corticosteroids not applied to the scalp).

  • Use within 6 months prior to screening of:

    • Minoxidil (topical or oral)
    • Finasteride (topical or oral)
    • Anti-androgenic drugs (e.g., spironolactone, cyproterone acetate, flutamide, bicalutamide)
    • Prostaglandin analogs applied to the scalp
    • Estrogen or progesterone topical preparations
    • Tamoxifen
    • Drugs associated with hypertrichosis (e.g., cyclosporine, phenytoin)
    • Drugs associated with hair loss (e.g., valproic acid)
  • Participation in another clinical trial within 1 month prior to screening or during this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: VENEZE Peptide factor hair serum
Participants in this arm will receive the VENEZE peptide factor hair serum applied topically to the scalp for 24 weeks.
Other: Veneze peptide hair serum
Participants will apply the VENEZE peptide factor hair serum to the affected scalp areas twice daily for 24 weeks according to the study protocol
Other Names:
  • Hair growth peptide serum
Active Comparator: Topical 2% minoxidil solution
Participants in this arm will receive 2% minoxidil solution applied topically to the scalp for 24 weeks.
Drug: Topical minoxidil
Topical minoxidil solution applied to the scalp according to the study protocol for the treatment of androgenetic alopecia.
Other Names:
  • Topical Minoxidil 2% solution

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in hair density from baseline
Time Frame: 12 and 24 weeks
Change from baseline in hair count within approximately 1 cm² target area at the vertex scalp, measured using standardized macrophotographic techniques at Weeks 12 and 24.
12 and 24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Investigator Global Aesthetic Improvement Scale
Time Frame: 12 and 24 weeks
Investigator assessment of treatment response using the Global Aesthetic Improvement Scale at the vertex and frontal scalp regions at baseline, week 12, and week 24.
12 and 24 weeks
Change in androgenetic alopecia severity
Time Frame: 12 and 24 weeks
Change in AGA severity based on Norwood-Hamilton classification in males and Ludwig classification in females at baseline, week 12, and week 24.
12 and 24 weeks
Patient Global Assessment of hair growth
Time Frame: 12 and 24 weeks
Change in patient-reported hair growth and satisfaction assessed using Patient Global Assessment (PGA) and Hair Growth Questionnaire scores at baseline, week 12, and week 24.
12 and 24 weeks
Incidence of adverse events
Time Frame: 24 weeks
Incidence and severity of treatment-related adverse events recorded from baseline until the end of the study.
24 weeks
Change in hair diameter and terminal hair count from baseline
Time Frame: 12 and 24 weeks
Change from baseline in hair diameter and the number of terminal hairs within approximately 1 cm² target area at the vertex scalp, measured using standardized macrophotographic techniques at Weeks 12 and 24.
12 and 24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Institute of Dermatology, Thailand

Collaborators

MEDEZE Cosmeceutical Company Limited

Investigators

  • Principal Investigator: Chinmanat Lekhavat, MD, PhD, Institute of dermatology
  • Principal Investigator: Suchanaree Laitrakul, MD, Institute of dermatology

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 5, 2026

Primary Completion (Estimated)

November 30, 2026

Study Completion (Estimated)

November 30, 2026

Study Registration Dates

First Submitted

April 11, 2026

First Submitted That Met QC Criteria

April 11, 2026

First Posted (Actual)

April 17, 2026

Study Record Updates

Last Update Posted (Actual)

May 13, 2026

Last Update Submitted That Met QC Criteria

May 9, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 031/2568
  • IRB-IOD-031/2568 (Other Identifier: Institute of Dermatology, Thailand)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Androgenetic Alopecia (AGA)

Clinical Trials on Veneze peptide hair serum

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe